Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence
CONCLUSION: BC risk prediction models and SNPs panels should not be automatically used in clinical practice in different populations without prior population-based validation. In our population the addition of an 18SNPs PRS to questionnaire-based risk factors in the Tyrer-Cuzick algorithm in general did not improve BC risk stratification, however, some improvements were observed at higher BC risk scores and could be valuable in distinguishing women at intermediate and high risk of BC.PMID:37857130 | PMC:PMC10587756 | DOI:10.1016/j.breast.2023.103590 (Source: Breast)
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Tja ša Oblak Petra Škerl Benjamin J Narang Rok Blagus Mateja Krajc Srdjan Novakovi ć Janez Žgajnar Source Type: research
Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients
Breast. 2023 Oct 14;72:103592. doi: 10.1016/j.breast.2023.103592. Online ahead of print.ABSTRACTAxillary staging is an important prognostic factor in breast cancer, being sentinel lymph node biopsy (SLNB) the gold standard staging method in early stages. However, in clinically node positive (cN+) patients who converted to clinically node-negative (cN0) after primary systemic therapy (PST) the axillary staging method during surgery remains controversial. There are at least three validated methods: SLNB, targeted axillary dissection (TAD) and marking axillary nodes with radioactive iodine seeds (MARI) procedure. Our house be...
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Benigno Acea-Nebril Alejandra Garc ía-Novoa Alberto Bouz ón Alejandro Carlota D íaz Carballada Carmen Conde Iglesias Source Type: research
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
CONCLUSIONS: The development of a program aimed at optimizing the prescription of Trastuzumab holds the potential to deliver significant cost-savings to hospitals while enhancing the quality of service provided to the patients. This optimization involves using H SC in monotherapy and BS IV in combination therapy administration.PMID:37857129 | PMC:PMC10587754 | DOI:10.1016/j.breast.2023.103588 (Source: Breast)
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Eric C Barat Marianne L E Arrii Annaelle Soubieux-Bourbon Mika ël Daouphars R émi Varin Patrick R Tilleul Source Type: research
Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence
CONCLUSION: BC risk prediction models and SNPs panels should not be automatically used in clinical practice in different populations without prior population-based validation. In our population the addition of an 18SNPs PRS to questionnaire-based risk factors in the Tyrer-Cuzick algorithm in general did not improve BC risk stratification, however, some improvements were observed at higher BC risk scores and could be valuable in distinguishing women at intermediate and high risk of BC.PMID:37857130 | PMC:PMC10587756 | DOI:10.1016/j.breast.2023.103590 (Source: Breast)
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Tja ša Oblak Petra Škerl Benjamin J Narang Rok Blagus Mateja Krajc Srdjan Novakovi ć Janez Žgajnar Source Type: research
Our house believes that: The clipped lymph node is the true sentinel node after neoadjuvant chemotherapy in N+ patients
Breast. 2023 Oct 14;72:103592. doi: 10.1016/j.breast.2023.103592. Online ahead of print.ABSTRACTAxillary staging is an important prognostic factor in breast cancer, being sentinel lymph node biopsy (SLNB) the gold standard staging method in early stages. However, in clinically node positive (cN+) patients who converted to clinically node-negative (cN0) after primary systemic therapy (PST) the axillary staging method during surgery remains controversial. There are at least three validated methods: SLNB, targeted axillary dissection (TAD) and marking axillary nodes with radioactive iodine seeds (MARI) procedure. Our house be...
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Benigno Acea-Nebril Alejandra Garc ía-Novoa Alberto Bouz ón Alejandro Carlota D íaz Carballada Carmen Conde Iglesias Source Type: research
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
CONCLUSIONS: The development of a program aimed at optimizing the prescription of Trastuzumab holds the potential to deliver significant cost-savings to hospitals while enhancing the quality of service provided to the patients. This optimization involves using H SC in monotherapy and BS IV in combination therapy administration.PMID:37857129 | DOI:10.1016/j.breast.2023.103588 (Source: Breast)
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Eric C Barat Marianne L E Arrii Annaelle Soubieux-Bourbon Mika ël Daouphars R émi Varin Patrick R Tilleul Source Type: research
Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence
CONCLUSION: BC risk prediction models and SNPs panels should not be automatically used in clinical practice in different populations without prior population-based validation. In our population the addition of an 18SNPs PRS to questionnaire-based risk factors in the Tyrer-Cuzick algorithm in general did not improve BC risk stratification, however, some improvements were observed at higher BC risk scores and could be valuable in distinguishing women at intermediate and high risk of BC.PMID:37857130 | DOI:10.1016/j.breast.2023.103590 (Source: Breast)
Source: Breast - October 19, 2023 Category: Cancer & Oncology Authors: Tja ša Oblak Petra Škerl Benjamin J Narang Rok Blagus Mateja Krajc Srdjan Novakovi ć Janez Žgajnar Source Type: research
Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
CONCLUSION: CAM was similar to an oligometastatic-like disease, and patients with these diseases may benefit from systemic treatment. Adding local treatment failed to significantly improve OS.PMID:37839139 | DOI:10.1016/j.breast.2023.103589 (Source: Breast)
Source: Breast - October 15, 2023 Category: Cancer & Oncology Authors: Qian Zhao Fan Yang Huai-Liang Wu Miao Mo Yun-Xiao Ling Guang-Yu Liu Source Type: research
Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
CONCLUSION: CAM was similar to an oligometastatic-like disease, and patients with these diseases may benefit from systemic treatment. Adding local treatment failed to significantly improve OS.PMID:37839139 | DOI:10.1016/j.breast.2023.103589 (Source: Breast)
Source: Breast - October 15, 2023 Category: Cancer & Oncology Authors: Qian Zhao Fan Yang Huai-Liang Wu Miao Mo Yun-Xiao Ling Guang-Yu Liu Source Type: research
Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease
CONCLUSION: CAM was similar to an oligometastatic-like disease, and patients with these diseases may benefit from systemic treatment. Adding local treatment failed to significantly improve OS.PMID:37839139 | DOI:10.1016/j.breast.2023.103589 (Source: Breast)
Source: Breast - October 15, 2023 Category: Cancer & Oncology Authors: Qian Zhao Fan Yang Huai-Liang Wu Miao Mo Yun-Xiao Ling Guang-Yu Liu Source Type: research
Consumer experiences of shame in clinical encounters for breast cancer treatment. "Who do you think you are- Angelina Jolie?"
CONCLUSIONS: Shame can be experienced in a range of situations, from scrutiny of the naked body to comments from health professionals. The impact of these experiences is profound, and the feelings of shame are carried for many years. These findings can inform strategies to support consumers and educate health professionals with the aim of reducing harm related to cancer treatment.PMID:37812962 | PMC:PMC10568266 | DOI:10.1016/j.breast.2023.103587 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: M E Brennan K Bell G Hamid J Gilchrist J Gillingham Source Type: research
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
CONCLUSION: We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.PMID:37812963 | PMC:PMC10568274 | DOI:10.1016/j.breast.2023.103586 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: Jan Paredes Mogica Haiming Tang Yuanxin Liang Minghao Zhong Pei Hui Malini Harigopal Uma Krishnamurti Neal A Fischbach Haiying Zhan Source Type: research
Consumer experiences of shame in clinical encounters for breast cancer treatment. "Who do you think you are- Angelina Jolie?"
CONCLUSIONS: Shame can be experienced in a range of situations, from scrutiny of the naked body to comments from health professionals. The impact of these experiences is profound, and the feelings of shame are carried for many years. These findings can inform strategies to support consumers and educate health professionals with the aim of reducing harm related to cancer treatment.PMID:37812962 | PMC:PMC10568266 | DOI:10.1016/j.breast.2023.103587 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: M E Brennan K Bell G Hamid J Gilchrist J Gillingham Source Type: research
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
CONCLUSION: We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.PMID:37812963 | PMC:PMC10568274 | DOI:10.1016/j.breast.2023.103586 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: Jan Paredes Mogica Haiming Tang Yuanxin Liang Minghao Zhong Pei Hui Malini Harigopal Uma Krishnamurti Neal A Fischbach Haiying Zhan Source Type: research
Consumer experiences of shame in clinical encounters for breast cancer treatment. "Who do you think you are- Angelina Jolie?"
CONCLUSIONS: Shame can be experienced in a range of situations, from scrutiny of the naked body to comments from health professionals. The impact of these experiences is profound, and the feelings of shame are carried for many years. These findings can inform strategies to support consumers and educate health professionals with the aim of reducing harm related to cancer treatment.PMID:37812962 | PMC:PMC10568266 | DOI:10.1016/j.breast.2023.103587 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: M E Brennan K Bell G Hamid J Gilchrist J Gillingham Source Type: research
